On May 11, 2021, Wendy Johnson notified Reneo Pharmaceuticals, Inc. of her intention to retire from her position as the company's Chief Development Officer, effective on or before December 31, 2021, to pursue personal interests. The Company will promptly commence a formal search for a new Chief Development Officer and Ms. Johnson has agreed to assist in the process of identifying such a replacement prior to her retirement.